famotidine has been researched along with Bone Loss, Osteoclastic in 3 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lesclous, P | 3 |
| Guez, D | 2 |
| Baroukh, B | 3 |
| Vignery, A | 1 |
| Saffar, JL | 3 |
| Fouilloux, I | 1 |
| Duplan, MB | 1 |
| Cherruau, M | 1 |
| Schramm, F | 1 |
| Gallina, S | 1 |
3 other studies available for famotidine and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Histamine participates in the early phase of trabecular bone loss in ovariectomized rats.
Topics: Animals; Body Weight; Bone Resorption; Cimetidine; Famotidine; Female; Femur; Histamine; Immunohisto | 2004 |
Mast cell activation and degranulation occur early during induction of periosteal bone resorption.
Topics: Animals; Bone Resorption; Cell Degranulation; Famotidine; Histamine H2 Antagonists; Histamine Releas | 2006 |
Histamine mediates osteoclastic resorption only during the acute phase of bone loss in ovariectomized rats.
Topics: Animals; Bone Resorption; Famotidine; Female; Histamine; Histamine H2 Antagonists; Osteoclasts; Ovar | 2006 |